Disclosures for "Steroid Use after the Inaugural Attack is a Meaningful Clinical Prognosticator in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease"
-
Dr. Tanasescu has received personal compensation for serving as an employee of Merck. Dr. Tanasescu has received personal compensation for serving as an employee of Novartis. Dr. Tanasescu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Tanasescu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Tanasescu has received research support from UK MRC grant MR/T024402/1.
-
Mr. Human has nothing to disclose.
-
Author has nothing to disclose
-
Dr. Tench has nothing to disclose.
-
Dr. Gilmartin has nothing to disclose.
-
Dr. Siriratnam has nothing to disclose.
-
The institution of Dr. Rocchi has received research support from Ectrims.
-
Dr. Hargovan-Lalloo has nothing to disclose.
-
Dr. Gran has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gilead. Dr. Gran has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche UK. Dr. Gran has received publishing royalties from a publication relating to health care.
-
Dr. The has nothing to disclose.
-
Author has nothing to disclose
-
Dr. Huda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen.